HealthcareServices

Neuroendocrine Carcinoma Market 2026–2030: Forecasting Business Opportunities Ahead

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neuroendocrine carcinoma market from 2026–2035 with trusted insights from The Business Research Company

How is the Neuroendocrine Carcinoma Market size predicted to change over the forecast window of 2026–2035?_x000D_

The market size for neuroendocrine carcinoma has experienced substantial growth in recent years. Its valuation is set to climb from $1.75 billion in 2025 to $1.88 billion in 2026, at a compound annual growth rate (CAGR) of 7.3%. This historical expansion can be linked to the increasing prevalence of neuroendocrine carcinoma, enhanced use of imaging for early detection, the early adoption of surgical tumor removal, the development of initial chemotherapy protocols, and a growing clinical awareness of nec subtypes._x000D_

_x000D_

The neuroendocrine carcinoma market is anticipated to show significant expansion over the coming years, with projections indicating a rise to $2.47 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This projected growth is largely due to the wider application of targeted biologic therapies, increased funding for immunotherapy research, the greater accessibility of precision diagnostic instruments, advancements in radiotherapy systems, and the expanding establishment of multidisciplinary oncology centers. Prominent trends expected during this period encompass the increasing uptake of chemotherapy for managing aggressive tumors, more frequent use of targeted therapies in advanced nec cases, greater reliance on radiotherapy for localized tumor control, the broadened scope of diagnostic methods involving biopsy and serology, and a heightened need for multidisciplinary approaches to treatment planning._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp_x000D_

_x000D_

Which Drivers Are Contributing To The Expansion Of The Neuroendocrine Carcinoma Market?_x000D_

The expansion of targeted therapies is projected to significantly drive the neuroendocrine carcinoma market forward. These therapies are specific treatments designed to precisely target and interrupt the molecular processes or genetic alterations that contribute to a disease, particularly cancer. The demand for targeted therapies is increasing due to their precision in addressing specific genetic mutations, advancements in personalized medicine, and improved patient outcomes with fewer side effects. Neuroendocrine carcinoma facilitates the development of targeted therapies that specifically address the tumor’s genetic and biochemical profiles, thereby enhancing treatment precision and effectiveness. For instance, in July 2023, a report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, noted that at the end of Q1 2023, there were 247 gene therapies in Phase II, but this figure climbed by 5% to reach 260 by the end of Q2. Therefore, the growth of targeted therapies is propelling the neuroendocrine carcinoma market._x000D_

_x000D_

What Segment Categories Are Covered In The Neuroendocrine Carcinoma Market?_x000D_

The neuroendocrine carcinoma market covered in this report is segmented –_x000D_

_x000D_

1) By Type: Gastroenteropancreatic Neuroendocrine Tumors, Carcinoid Tumors, Pheochromocytoma, Medullary Thyroid Carcinoma_x000D_

2) By Diagnostic Tools: Imaging, Biopsy, Serology_x000D_

3) By Treatment: Chemotherapy, Radiotherapy, Surgery, Other Treatments_x000D_

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_

5) By End-User: Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers_x000D_

_x000D_

Subsegments:_x000D_

1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs), Small Intestinal Neuroendocrine Tumors, Gastric Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors_x000D_

2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors, Gastrointestinal Carcinoid Tumors_x000D_

3) By Pheochromocytoma: Adrenal Pheochromocytoma, Extra-Adrenal Paraganglioma_x000D_

4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma, Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)_x000D_

_x000D_

How Are Emerging Trends Affecting The Progression Of The Neuroendocrine Carcinoma Market?_x000D_

Companies operating within the neuroendocrine carcinoma market are concentrating on developing advanced therapies, such as targeted radiopharmaceutical therapy, to enhance treatment precision and improve patient outcomes. Targeted radiopharmaceutical therapy employs radioactive molecules that specifically locate and deliver radiation to cancer cells, thereby minimizing damage to healthy tissue. For example, in September 2024, Abdera Therapeutics Inc., a biotechnology company based in Canada, secured orphan drug designation from the Food and Drug Administration (FDA) for ABD-147 for addressing neuroendocrine carcinoma. This compound is engineered to selectively target tumors that express the DLL3 protein, often overexpressed in aggressive neuroendocrine cancers, including small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). The designation grants significant development advantages, such as tax credits for clinical trials and potential market exclusivity, positioning ABD-147 as a valuable treatment candidate in this specialized oncology field._x000D_

_x000D_

Which Major Firms Are Strengthening Their Position In The Neuroendocrine Carcinoma Market?_x000D_

Major companies operating in the neuroendocrine carcinoma market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Amgen Inc., Boehringer Ingelheim GmbH, Exelixis Inc., Lantheus Holdings Inc., HUTCHMED Limited, Dana-Farber Cancer Institute Inc., Abdera Therapeutics Inc., Orano Med S.A, Eckert & Ziegler Radiopharma GmbH, Callisto Pharmaceuticals Inc., RadioMedix Inc., Clarity Pharmaceuticals Limited, Delcath Systems Inc., Provectus Biopharmaceuticals Inc._x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report_x000D_

_x000D_

Which Global Regions Are Shaping The Competitive Landscape Of The Neuroendocrine Carcinoma Market?_x000D_

North America was the largest region in the neuroendocrine carcinoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Neuroendocrine Carcinoma Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Neuroendocrine Carcinoma Market 2026, By The Business Research Company#_x000D_

_x000D_

Basal Cell Carcinoma Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report_x000D_

_x000D_

Basal Cell Carcinoma Treatment Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/basal-cell-carcinoma-treatment-global-market-report_x000D_

_x000D_